Vertex Pharmaceuticals slumps as experimental non-opioid painkiller fails mid-stage trial

Vertex Pharmaceuticals Incorporated

04/08/2025 21:27

** Shares of Vertex Pharmaceuticals VRTX.O down 14% at $403.00 in extended trading

** Co says will not continue development of its experimental non-opioid painkiller as a solo treatment after it failed to meet the main goal of a mid-stage trial

** VRTX reports Q2 revenue of $2.96 billion, beating estimates of $2.91 billion - LSEG

** Co maintains annual forecast; adds forecast includes an immaterial cost impact from tariffs

** YTD, shares up 17% as of last close

 (Reporting by Juveria Tabassum in Bengaluru)

 ((Juveria.Tabassum@thomsonreuters.com))